Cathepsin E Prevents Tumor Growth and Metastasis by Catalyzing the Proteolytic Release of Soluble TRAIL from Tumor Cell Surface

The aspartic proteinase cathepsin E is expressed predominantly in cells of the immune system and highly secreted by activated phagocytes, and deficiency of cathepsin E in mice results in a phenotype affecting immune responses. However, because physiologic substrates for cathepsin E have not yet been...

Full description

Saved in:
Bibliographic Details
Published inCancer research (Chicago, Ill.) Vol. 67; no. 22; pp. 10869 - 10878
Main Authors KAWAKUBO, Tomoyo, OKAMOTO, Kuniaki, IWATA, Jun-Ichi, SHIN, Masashi, OKAMOTO, Yoshiko, YASUKOCHI, Atsushi, NAKAYAMA, Keiichi I, KADOWAKI, Tomoko, TSUKUBA, Takayuki, YAMAMOTO, Kenji
Format Journal Article
LanguageEnglish
Published Philadelphia, PA American Association for Cancer Research 15.11.2007
Subjects
Online AccessGet full text

Cover

Loading…
Abstract The aspartic proteinase cathepsin E is expressed predominantly in cells of the immune system and highly secreted by activated phagocytes, and deficiency of cathepsin E in mice results in a phenotype affecting immune responses. However, because physiologic substrates for cathepsin E have not yet been identified, the relevance of these observations to the physiologic functions of this protein remains speculative. Here, we show that cathepsin E specifically induces growth arrest and apoptosis in human prostate carcinoma tumor cell lines without affecting normal cells by catalyzing the proteolytic release of soluble tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) from the cell surface. The antitumor activity of cathepsin E was corroborated by in vivo studies with mice bearing human and mouse tumor transplants. Administration of purified cathepsin E into human tumor xenografts in nude mice dose-dependently induced apoptosis in the tumor cells to inhibit tumor growth. The growth, viability, and metastasis of mouse B16 melanoma cells were also more profound in cathepsin E-deficient mice compared with those in the syngeneic wild-type and transgenic mice overexpressing cathepsin E. Taken together, the number of apoptotic tumor cells, as well as tumor-infiltrating activated macrophages, was apparently reduced in cathepsin E-deficient mice compared with those in the other two groups, implying the positive correlation of endogenous cathepsin E levels with the extent of tumor suppression in vivo. These results thus indicate that cathepsin E plays a substantial role in host defense against tumor cells through TRAIL-dependent apoptosis and/or tumor-associated macrophage-mediated cytotoxicity.
AbstractList The aspartic proteinase cathepsin E is expressed predominantly in cells of the immune system and highly secreted by activated phagocytes, and deficiency of cathepsin E in mice results in a phenotype affecting immune responses. However, because physiologic substrates for cathepsin E have not yet been identified, the relevance of these observations to the physiologic functions of this protein remains speculative. Here, we show that cathepsin E specifically induces growth arrest and apoptosis in human prostate carcinoma tumor cell lines without affecting normal cells by catalyzing the proteolytic release of soluble tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) from the cell surface. The antitumor activity of cathepsin E was corroborated by in vivo studies with mice bearing human and mouse tumor transplants. Administration of purified cathepsin E into human tumor xenografts in nude mice dose-dependently induced apoptosis in the tumor cells to inhibit tumor growth. The growth, viability, and metastasis of mouse B16 melanoma cells were also more profound in cathepsin E-deficient mice compared with those in the syngeneic wild-type and transgenic mice overexpressing cathepsin E. Taken together, the number of apoptotic tumor cells, as well as tumor-infiltrating activated macrophages, was apparently reduced in cathepsin E-deficient mice compared with those in the other two groups, implying the positive correlation of endogenous cathepsin E levels with the extent of tumor suppression in vivo. These results thus indicate that cathepsin E plays a substantial role in host defense against tumor cells through TRAIL-dependent apoptosis and/or tumor-associated macrophage-mediated cytotoxicity.
The aspartic proteinase cathepsin E is expressed predominantly in cells of the immune system and highly secreted by activated phagocytes, and deficiency of cathepsin E in mice results in a phenotype affecting immune responses. However, because physiologic substrates for cathepsin E have not yet been identified, the relevance of these observations to the physiologic functions of this protein remains speculative. Here, we show that cathepsin E specifically induces growth arrest and apoptosis in human prostate carcinoma tumor cell lines without affecting normal cells by catalyzing the proteolytic release of soluble tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) from the cell surface. The antitumor activity of cathepsin E was corroborated by in vivo studies with mice bearing human and mouse tumor transplants. Administration of purified cathepsin E into human tumor xenografts in nude mice dose-dependently induced apoptosis in the tumor cells to inhibit tumor growth. The growth, viability, and metastasis of mouse B16 melanoma cells were also more profound in cathepsin E-deficient mice compared with those in the syngeneic wild-type and transgenic mice overexpressing cathepsin E. Taken together, the number of apoptotic tumor cells, as well as tumor-infiltrating activated macrophages, was apparently reduced in cathepsin E-deficient mice compared with those in the other two groups, implying the positive correlation of endogenous cathepsin E levels with the extent of tumor suppression in vivo. These results thus indicate that cathepsin E plays a substantial role in host defense against tumor cells through TRAIL-dependent apoptosis and/or tumor-associated macrophage-mediated cytotoxicity. [Cancer Res 2007; 67(22):10869-78]
Abstract The aspartic proteinase cathepsin E is expressed predominantly in cells of the immune system and highly secreted by activated phagocytes, and deficiency of cathepsin E in mice results in a phenotype affecting immune responses. However, because physiologic substrates for cathepsin E have not yet been identified, the relevance of these observations to the physiologic functions of this protein remains speculative. Here, we show that cathepsin E specifically induces growth arrest and apoptosis in human prostate carcinoma tumor cell lines without affecting normal cells by catalyzing the proteolytic release of soluble tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) from the cell surface. The antitumor activity of cathepsin E was corroborated by in vivo studies with mice bearing human and mouse tumor transplants. Administration of purified cathepsin E into human tumor xenografts in nude mice dose-dependently induced apoptosis in the tumor cells to inhibit tumor growth. The growth, viability, and metastasis of mouse B16 melanoma cells were also more profound in cathepsin E–deficient mice compared with those in the syngeneic wild-type and transgenic mice overexpressing cathepsin E. Taken together, the number of apoptotic tumor cells, as well as tumor-infiltrating activated macrophages, was apparently reduced in cathepsin E–deficient mice compared with those in the other two groups, implying the positive correlation of endogenous cathepsin E levels with the extent of tumor suppression in vivo. These results thus indicate that cathepsin E plays a substantial role in host defense against tumor cells through TRAIL-dependent apoptosis and/or tumor-associated macrophage-mediated cytotoxicity. [Cancer Res 2007;67(22):10869–78]
Author KAWAKUBO, Tomoyo
OKAMOTO, Yoshiko
YASUKOCHI, Atsushi
NAKAYAMA, Keiichi I
YAMAMOTO, Kenji
OKAMOTO, Kuniaki
IWATA, Jun-Ichi
KADOWAKI, Tomoko
SHIN, Masashi
TSUKUBA, Takayuki
Author_xml – sequence: 1
  givenname: Tomoyo
  surname: KAWAKUBO
  fullname: KAWAKUBO, Tomoyo
  organization: Department of Pharmacology, Graduate School of Dental Science, Kyushu University, United States
– sequence: 2
  givenname: Kuniaki
  surname: OKAMOTO
  fullname: OKAMOTO, Kuniaki
  organization: Department of Dental Pharmacology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan
– sequence: 3
  givenname: Jun-Ichi
  surname: IWATA
  fullname: IWATA, Jun-Ichi
  organization: Department of Pharmacology, Graduate School of Dental Science, Kyushu University, United States
– sequence: 4
  givenname: Masashi
  surname: SHIN
  fullname: SHIN, Masashi
  organization: Department of Pharmacology, Graduate School of Dental Science, Kyushu University, United States
– sequence: 5
  givenname: Yoshiko
  surname: OKAMOTO
  fullname: OKAMOTO, Yoshiko
  organization: Department of Biochemistry, Daiichi University College of Pharmaceutical Sciences, Fukuoka, Japan
– sequence: 6
  givenname: Atsushi
  surname: YASUKOCHI
  fullname: YASUKOCHI, Atsushi
  organization: Department of Pharmacology, Graduate School of Dental Science, Kyushu University, United States
– sequence: 7
  givenname: Keiichi I
  surname: NAKAYAMA
  fullname: NAKAYAMA, Keiichi I
  organization: Department of Molecular and Cellular Biology, Medical Institute of Bioregulation, Kyushu University, United States
– sequence: 8
  givenname: Tomoko
  surname: KADOWAKI
  fullname: KADOWAKI, Tomoko
  organization: Department of Pharmacology, Graduate School of Dental Science, Kyushu University, United States
– sequence: 9
  givenname: Takayuki
  surname: TSUKUBA
  fullname: TSUKUBA, Takayuki
  organization: Department of Pharmacology, Graduate School of Dental Science, Kyushu University, United States
– sequence: 10
  givenname: Kenji
  surname: YAMAMOTO
  fullname: YAMAMOTO, Kenji
  organization: Department of Pharmacology, Graduate School of Dental Science, Kyushu University, United States
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19889352$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/18006832$$D View this record in MEDLINE/PubMed
BookMark eNqFkc1u1DAURi1URKeFRwB5A7sU_8SJsxxFpVQaCmqHtXXtuaFBiT3YSdGw4dXxqBFdVrJkWTrn-ur7zsiJDx4JecvZBedKf2SM6UKVtbhw4AtWF4KV-gVZcSV1UZelOiGr_8wpOUvpZ34qztQrcso1Y5WWYkX-tjDd4z71nl7SbxEf0E-JbucxRHoVw-_pnoLf0S84QcqnT9QeaHZgOPzp_Q-a5ayFCcNwmHpHb3FASEhDR-_CMNsB6fZ2fb2hXQzjMrfFYaB3c-zA4WvysoMh4ZvlPiffP11u28_F5uvVdbveFE5VbCpkZ0vg3HZKqUqA0hI4Nk3D0FoBlXDAGeelAifQ6h23SjFVOal3ZWmFrOU5-fA4dx_DrxnTZMY-ubwIeAxzMpVWrGq0fBYUrBI8Z5pB9Qi6GFKK2Jl97EeIB8OZOVZkjvGbY_ymXd8YVptjRdl7t3ww2xF3T9bSSQbeLwAkB0MXwbs-PXGN1o1UQv4DAzmbvA
CODEN CNREA8
CitedBy_id crossref_primary_10_1016_j_jmb_2008_12_028
crossref_primary_10_1038_s41467_017_02731_6
crossref_primary_10_1002_adbi_201800232
crossref_primary_10_1515_bc_2011_060
crossref_primary_10_1002_ijc_26032
crossref_primary_10_1016_j_pharmthera_2019_02_003
crossref_primary_10_1016_S1349_0079_11_80015_0
crossref_primary_10_1007_s00262_019_02368_y
crossref_primary_10_3390_cancers15102752
crossref_primary_10_1016_j_pan_2019_09_009
crossref_primary_10_1016_j_bbapap_2020_140465
crossref_primary_10_1186_s12929_016_0276_x
crossref_primary_10_3389_fimmu_2017_00203
crossref_primary_10_3390_cancers11070954
crossref_primary_10_1016_j_job_2011_10_001
crossref_primary_10_1089_acm_2011_0467
crossref_primary_10_3389_fimmu_2023_1209249
crossref_primary_10_3390_ijms18061227
crossref_primary_10_4049_immunohorizons_2000098
crossref_primary_10_1155_2011_834525
crossref_primary_10_1371_journal_pone_0056766
crossref_primary_10_1093_jb_mvr135
crossref_primary_10_1016_j_ajpath_2012_01_023
crossref_primary_10_1111_j_1471_4159_2008_05242_x
crossref_primary_10_1186_s12974_017_0891_9
crossref_primary_10_1111_febs_15637
crossref_primary_10_1016_j_bbrc_2008_10_034
crossref_primary_10_1515_bc_2010_087
crossref_primary_10_1002_2211_5463_13372
crossref_primary_10_1177_10915818211069270
crossref_primary_10_3390_cancers11050639
crossref_primary_10_1111_acel_13565
crossref_primary_10_4049_jimmunol_1102173
crossref_primary_10_1016_j_semcancer_2019_05_006
crossref_primary_10_3109_15412555_2015_1057273
crossref_primary_10_1007_s00018_010_0469_5
crossref_primary_10_1371_journal_pone_0132477
crossref_primary_10_1016_j_cbpc_2017_11_005
crossref_primary_10_1039_C7NR01469D
crossref_primary_10_1371_journal_pone_0125816
crossref_primary_10_1093_molehr_gau008
crossref_primary_10_1155_2012_316432
crossref_primary_10_3390_cancers11040568
crossref_primary_10_1038_s41598_019_38809_y
crossref_primary_10_1159_000488770
crossref_primary_10_3892_ijo_2013_1790
crossref_primary_10_1007_s00109_013_1021_5
crossref_primary_10_1074_jbc_M109_035105
crossref_primary_10_1016_j_ccell_2021_05_005
crossref_primary_10_1245_s10434_014_4155_y
crossref_primary_10_3390_biomedicines12010079
crossref_primary_10_1002_psc_2453
crossref_primary_10_1021_pr300758c
crossref_primary_10_1016_j_cellimm_2023_104718
crossref_primary_10_3390_cancers10030077
crossref_primary_10_1016_j_dci_2020_103607
crossref_primary_10_3389_fimmu_2019_01530
crossref_primary_10_1016_j_bbapap_2011_05_022
crossref_primary_10_1016_j_toxlet_2017_03_008
crossref_primary_10_3390_cells13060521
crossref_primary_10_1158_0008_5472_CAN_07_5154
crossref_primary_10_3349_ymj_2010_51_5_653
crossref_primary_10_1097_MPA_0000000000000610
crossref_primary_10_1093_carcin_bgt373
Cites_doi 10.1515/BC.2005.036
10.1001/archsurg.136.7.804
10.1002/(SICI)1521-4141(199805)28:05<1492::AID-IMMU1492>3.0.CO;2-X
10.1007/978-3-0348-8737-3_5
10.1002/eji.1830220626
10.1126/science.281.5381.1305
10.1093/oxfordjournals.jbchem.a003247
10.1002/path.1584
10.1111/j.1432-1033.1978.tb12772.x
10.1158/1078-0432.CCR-05-0259
10.1084/jem.189.8.1343
10.1021/bi992242l
10.1006/cimm.2001.1896
10.1016/j.cell.2006.01.007
10.1111/j.1365-2613.2006.00478.x
10.1038/sj.emboj.7600464
10.1084/jem.189.9.1451
10.1016/S1097-2765(00)80207-5
10.1093/jb/mvj132
10.1016/S0304-3835(98)00299-7
10.1159/000090154
10.1126/science.6879183
10.1046/j.1471-4159.1998.70052045.x
10.4049/jimmunol.163.10.5358
10.1093/jb/mvg216
10.1038/385729a0
10.1084/jem.190.8.1155
10.1158/1078-0432.CCR-04-2409
10.1016/S0952-7915(98)80224-0
10.1074/jbc.M108382200
10.1016/S1074-7613(00)80100-4
10.1016/1074-7613(95)90057-8
10.1002/jlb.64.4.419
10.1084/jem.193.6.727
10.1038/nrc1821
10.4049/jimmunol.174.4.1791
10.1074/jbc.M909721199
10.1074/jbc.M604143200
10.1002/(SICI)1521-4141(199803)28:03<973::AID-IMMU973>3.0.CO;2-T
10.1038/sj.cr.7290236
10.1097/00008390-199201000-00001
10.4049/jimmunol.163.4.1906
10.1074/jbc.271.22.12687
10.2330/joralbiosci.48.218
10.2152/jmi.52.1
10.1016/0304-4165(89)90130-X
10.4049/jimmunol.141.7.2407
ContentType Journal Article
Copyright 2008 INIST-CNRS
Copyright_xml – notice: 2008 INIST-CNRS
DBID IQODW
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7TO
H94
7X8
DOI 10.1158/0008-5472.can-07-2048
DatabaseName Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
Oncogenes and Growth Factors Abstracts
AIDS and Cancer Research Abstracts
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
Oncogenes and Growth Factors Abstracts
AIDS and Cancer Research Abstracts
MEDLINE - Academic
DatabaseTitleList MEDLINE
Oncogenes and Growth Factors Abstracts
CrossRef
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1538-7445
EndPage 10878
ExternalDocumentID 10_1158_0008_5472_CAN_07_2048
18006832
19889352
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
-ET
.55
.GJ
08R
18M
29B
2WC
34G
39C
3O-
476
53G
5GY
5RE
5VS
6J9
8WZ
A6W
AAPBV
AAUGY
ABOCM
ABPTK
ACGFO
ACIWK
ACPRK
ACSVP
ADBBV
ADCOW
ADNWM
AENEX
AETEA
AFFNX
AFHIN
AFOSN
AFRAH
AI.
ALMA_UNASSIGNED_HOLDINGS
BAWUL
BTFSW
C1A
CS3
D0S
DIK
DU5
EBS
EJD
F5P
FRP
GX1
H13
IH2
IQODW
J5H
KQ8
L7B
LSO
MVM
OHT
OK1
P0W
P2P
PQQKQ
RCR
RHF
RHI
RNS
SJN
TR2
UDS
VH1
W2D
W8F
WH7
WHG
WOQ
X7M
XFK
XJT
YKV
YZZ
ZA5
ZCG
ZGI
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7TO
H94
7X8
ID FETCH-LOGICAL-c560t-3fb4a11bf55562a583a1e9990ebb2a62ca101145ac2eb8d1b55056c38d44b2373
ISSN 0008-5472
IngestDate Fri Oct 25 21:52:14 EDT 2024
Fri Oct 25 01:37:58 EDT 2024
Thu Sep 26 17:49:20 EDT 2024
Sat Sep 28 07:48:21 EDT 2024
Sun Oct 29 17:07:12 EDT 2023
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 22
Keywords Enzyme
Cathepsin E
Cytokine
Soluble form
Metastasis
Malignant tumor
Cell surface
Prevention
Peptidases
Tumor growth
Tumor necrosis factor
Hydrolases
TNF related apoptosis inducing ligand
Aspartic endopeptidases
Tumor cell
Cancer
Language English
License CC BY 4.0
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c560t-3fb4a11bf55562a583a1e9990ebb2a62ca101145ac2eb8d1b55056c38d44b2373
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://aacr.figshare.com/articles/journal_contribution/Supplementary_Materials_from_Cathepsin_E_Prevents_Tumor_Growth_and_Metastasis_by_Catalyzing_the_Proteolytic_Release_of_Soluble_TRAIL_from_Tumor_Cell_Surface/22371227/1/files/39816323.pdf
PMID 18006832
PQID 20621547
PQPubID 23462
PageCount 10
ParticipantIDs proquest_miscellaneous_68506983
proquest_miscellaneous_20621547
crossref_primary_10_1158_0008_5472_CAN_07_2048
pubmed_primary_18006832
pascalfrancis_primary_19889352
PublicationCentury 2000
PublicationDate 2007-11-15
PublicationDateYYYYMMDD 2007-11-15
PublicationDate_xml – month: 11
  year: 2007
  text: 2007-11-15
  day: 15
PublicationDecade 2000
PublicationPlace Philadelphia, PA
PublicationPlace_xml – name: Philadelphia, PA
– name: United States
PublicationTitle Cancer research (Chicago, Ill.)
PublicationTitleAlternate Cancer Res
PublicationYear 2007
Publisher American Association for Cancer Research
Publisher_xml – name: American Association for Cancer Research
References 2022061623363084900_B30
2022061623363084900_B33
2022061623363084900_B34
2022061623363084900_B31
2022061623363084900_B32
2022061623363084900_B37
2022061623363084900_B38
2022061623363084900_B35
2022061623363084900_B36
2022061623363084900_B39
2022061623363084900_B22
2022061623363084900_B23
2022061623363084900_B20
2022061623363084900_B21
2022061623363084900_B26
2022061623363084900_B27
2022061623363084900_B24
2022061623363084900_B25
2022061623363084900_B28
2022061623363084900_B29
2022061623363084900_B1
2022061623363084900_B5
2022061623363084900_B4
2022061623363084900_B3
2022061623363084900_B2
2022061623363084900_B50
2022061623363084900_B11
2022061623363084900_B12
2022061623363084900_B10
2022061623363084900_B15
2022061623363084900_B16
2022061623363084900_B13
2022061623363084900_B14
2022061623363084900_B19
2022061623363084900_B17
2022061623363084900_B18
2022061623363084900_B40
2022061623363084900_B41
2022061623363084900_B44
2022061623363084900_B45
2022061623363084900_B42
2022061623363084900_B43
2022061623363084900_B9
2022061623363084900_B48
2022061623363084900_B8
2022061623363084900_B49
2022061623363084900_B7
2022061623363084900_B46
2022061623363084900_B6
2022061623363084900_B47
References_xml – ident: 2022061623363084900_B21
  doi: 10.1515/BC.2005.036
– ident: 2022061623363084900_B45
  doi: 10.1001/archsurg.136.7.804
– ident: 2022061623363084900_B40
  doi: 10.1002/(SICI)1521-4141(199805)28:05<1492::AID-IMMU1492>3.0.CO;2-X
– ident: 2022061623363084900_B3
  doi: 10.1007/978-3-0348-8737-3_5
– ident: 2022061623363084900_B6
  doi: 10.1002/eji.1830220626
– ident: 2022061623363084900_B15
  doi: 10.1126/science.281.5381.1305
– ident: 2022061623363084900_B22
  doi: 10.1093/oxfordjournals.jbchem.a003247
– ident: 2022061623363084900_B11
  doi: 10.1002/path.1584
– ident: 2022061623363084900_B23
  doi: 10.1111/j.1432-1033.1978.tb12772.x
– ident: 2022061623363084900_B14
  doi: 10.1158/1078-0432.CCR-05-0259
– ident: 2022061623363084900_B30
  doi: 10.1084/jem.189.8.1343
– ident: 2022061623363084900_B27
  doi: 10.1021/bi992242l
– ident: 2022061623363084900_B44
– ident: 2022061623363084900_B43
  doi: 10.1006/cimm.2001.1896
– ident: 2022061623363084900_B48
  doi: 10.1016/j.cell.2006.01.007
– ident: 2022061623363084900_B47
  doi: 10.1111/j.1365-2613.2006.00478.x
– ident: 2022061623363084900_B50
  doi: 10.1038/sj.emboj.7600464
– ident: 2022061623363084900_B39
  doi: 10.1084/jem.189.9.1451
– ident: 2022061623363084900_B19
  doi: 10.1016/S1097-2765(00)80207-5
– ident: 2022061623363084900_B9
  doi: 10.1093/jb/mvj132
– ident: 2022061623363084900_B34
  doi: 10.1016/S0304-3835(98)00299-7
– ident: 2022061623363084900_B12
  doi: 10.1159/000090154
– ident: 2022061623363084900_B36
  doi: 10.1126/science.6879183
– ident: 2022061623363084900_B33
  doi: 10.1046/j.1471-4159.1998.70052045.x
– ident: 2022061623363084900_B41
  doi: 10.4049/jimmunol.163.10.5358
– ident: 2022061623363084900_B8
  doi: 10.1093/jb/mvg216
– ident: 2022061623363084900_B38
  doi: 10.1038/385729a0
– ident: 2022061623363084900_B32
  doi: 10.1084/jem.190.8.1155
– ident: 2022061623363084900_B13
  doi: 10.1158/1078-0432.CCR-04-2409
– ident: 2022061623363084900_B28
  doi: 10.1016/S0952-7915(98)80224-0
– ident: 2022061623363084900_B4
  doi: 10.1074/jbc.M108382200
– ident: 2022061623363084900_B18
  doi: 10.1016/S1074-7613(00)80100-4
– ident: 2022061623363084900_B16
  doi: 10.1016/1074-7613(95)90057-8
– ident: 2022061623363084900_B29
  doi: 10.1002/jlb.64.4.419
– ident: 2022061623363084900_B49
  doi: 10.1084/jem.193.6.727
– ident: 2022061623363084900_B2
  doi: 10.1038/nrc1821
– ident: 2022061623363084900_B7
  doi: 10.4049/jimmunol.174.4.1791
– ident: 2022061623363084900_B26
  doi: 10.1074/jbc.M909721199
– ident: 2022061623363084900_B42
– ident: 2022061623363084900_B10
  doi: 10.1074/jbc.M604143200
– ident: 2022061623363084900_B20
  doi: 10.1002/(SICI)1521-4141(199803)28:03<973::AID-IMMU973>3.0.CO;2-T
– ident: 2022061623363084900_B25
– ident: 2022061623363084900_B24
  doi: 10.1038/sj.cr.7290236
– ident: 2022061623363084900_B37
  doi: 10.1097/00008390-199201000-00001
– ident: 2022061623363084900_B31
  doi: 10.4049/jimmunol.163.4.1906
– ident: 2022061623363084900_B17
  doi: 10.1074/jbc.271.22.12687
– ident: 2022061623363084900_B46
  doi: 10.2330/joralbiosci.48.218
– ident: 2022061623363084900_B1
  doi: 10.2152/jmi.52.1
– ident: 2022061623363084900_B5
  doi: 10.1016/0304-4165(89)90130-X
– ident: 2022061623363084900_B35
  doi: 10.4049/jimmunol.141.7.2407
SSID ssj0005105
Score 2.2503726
Snippet The aspartic proteinase cathepsin E is expressed predominantly in cells of the immune system and highly secreted by activated phagocytes, and deficiency of...
Abstract The aspartic proteinase cathepsin E is expressed predominantly in cells of the immune system and highly secreted by activated phagocytes, and...
SourceID proquest
crossref
pubmed
pascalfrancis
SourceType Aggregation Database
Index Database
StartPage 10869
SubjectTerms Animals
Antineoplastic agents
Apoptosis
Biological and medical sciences
Carcinoma - metabolism
Cathepsin E - metabolism
Cell Membrane - metabolism
Humans
Immune System
Male
Medical sciences
Mice
Mice, Inbred C57BL
Mice, Transgenic
Models, Biological
Neoplasm Metastasis
Neoplasms - metabolism
Pharmacology. Drug treatments
Prostatic Neoplasms - metabolism
TNF-Related Apoptosis-Inducing Ligand - metabolism
Tumors
Title Cathepsin E Prevents Tumor Growth and Metastasis by Catalyzing the Proteolytic Release of Soluble TRAIL from Tumor Cell Surface
URI https://www.ncbi.nlm.nih.gov/pubmed/18006832
https://search.proquest.com/docview/20621547
https://search.proquest.com/docview/68506983
Volume 67
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEF6FIiEkhHgTHmUP3CKH-LF-HKMoqLSkAppKvVm79lqpmtpRYitKL_xFfhIzu2s7KS2iXKzEzo6tzOfdmdn5Zgj5GDHOuMOFldqRsLxMcku4dmq5MoskhzVXpCpB9tg_OPUOz9hZp_NrK2upKkU_ubqRV_I_WoVzoFdkyd5Bs41QOAGfQb9wBA3D8Z90rOh7C_D2e-OeqcW06k2ry2KJMaW1Ya1NZMnBBsTKI2BrjjBes7mqWVLfsE5DMd-UKqF-jps1mscyr5BTNf0x_PJVc1C03BHG-k6qZcaT61UOErnsmdpBM7U5rLM81Cw0n_e3Yg5HfM0vKqEuTYvLYlM0sd4LDthRF46q_BzM2wa7a64N3cMqt86TWXPhZKbLIEz4ChtD7YQxAuTzaSJnMzWHFvN0H5--bGfjwNP1JuvpWnfvMLDUnGYz-WLTqGhrJYfvuj3Qn8sEC3Vepb5lfzQ8xngtFjFu18U6F-DactkkMSr3iYW4fR_GKCYGMfEgiFHMPXLfwdKDmCbwva1fz0xSbX1nwykDMZ9ufJoda-nRgq_gxc10x5XbXSJlGk2fkMfGp6FDDdCnpCPzZ-TBxGRtPCc_G5zSMa1xShWeqMYpBZzSFqdUbGiLUwqD6RZOqcEpLTJqcEoVTini1MhFnFKD0xfk9PN4OjqwTOMPKwEDvLTcTHjctkXGGJjnnIUutyV4MgMphMN9J-E2-vGMJ44UYWoLdLP9xA1TzxOOG7gvyV5e5PI1oTAijYQdiEGUeb4PxhiLwIeOvMgXrkz9LunXf3C80PVd4r8qtkv2d9TQjopCsP2Z0yUfar3EMFXj_hvPZVGtYLgPBrYX3P4LH-tHRqHbJa-0QlvpIZK5XOfNXZ_3LXnYvm7vyF65rOR7sKNLsa-g-RucHMKx
link.rule.ids 315,783,787,27937,27938
linkProvider Colorado Alliance of Research Libraries
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Cathepsin+E+Prevents+Tumor+Growth+and+Metastasis+by+Catalyzing+the+Proteolytic+Release+of+Soluble+TRAIL+from+Tumor+Cell+Surface&rft.jtitle=Cancer+research+%28Chicago%2C+Ill.%29&rft.au=Kawakubo%2C+Tomoyo&rft.au=Okamoto%2C+Kuniaki&rft.au=Iwata%2C+Jun-ichi&rft.au=Shin%2C+Masashi&rft.date=2007-11-15&rft.issn=0008-5472&rft.eissn=1538-7445&rft.volume=67&rft.issue=22&rft.spage=10869&rft.epage=10878&rft_id=info:doi/10.1158%2F0008-5472.CAN-07-2048&rft.externalDBID=n%2Fa&rft.externalDocID=10_1158_0008_5472_CAN_07_2048
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0008-5472&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0008-5472&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0008-5472&client=summon